Cargando…
Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
PURPOSE: The aim of this study is to investigate the effect of hepatic or renal impairment on the pharmacokinetics of a single 130-mg evacetrapib dose. METHODS: Two open-label, parallel-design studies in males and females with normal hepatic function or Child-Pugh mild, moderate, or severe hepatic i...
Autores principales: | Small, David S., Zhang, Wei, Royalty, Jane, Cannady, Ellen A., Downs, Delyn, Ortega, Demetrio, Suico, Jeffrey G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834099/ https://www.ncbi.nlm.nih.gov/pubmed/26857125 http://dx.doi.org/10.1007/s00228-016-2017-1 |
Ejemplares similares
-
Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects
por: Small, David S., et al.
Publicado: (2016) -
A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State
por: Small, David S., et al.
Publicado: (2015) -
Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment
por: Wu, Wanhong, et al.
Publicado: (2021) -
Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015) -
Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment
por: Watanabe, Akiko, et al.
Publicado: (2021)